Can Mitochondrial DNA Mutations Be Used as a Biomarker for Endometrial Cancer?



T. L. Sauerbrunn¹, P. Khadka¹, S. Lanier¹, C. Young¹, K. Groesch^{3,6}, K. Robinson^{4,7}, A. Braundmeier-Fleming^{5,6,7}, R. Sachidanandam⁸, D. B. Hales^{1,2,6,7}, L. Brard^{6,7}, & M. Young^{1,7}

¹Biochemistry & Molecular Biology, Carbondale, ²Physiology, Carbondale, ³Center for Clinical Research, Springfield, ⁴Division of Hematology/Oncology - Dept of Internal Medicine, Springfield, ⁵Medical Microbiology, Immunology & Cell Biology, Springfield, ⁶Obstetrics & Gynecology, Springfield, ⁷Simmons Cancer Institute, Springfield, ⁸Girihlet Inc, Oakland, CA

Introduction

Endometrial cancer, also known as EC, had 417,000 new cases in 2020 and is the 6th most common cancer in women and the 15th most common cancer overall (wcrf.org). Endometrial cancer affects the endometrium, the inner lining of the uterus. When endometrial cancer occurs, something causes changes, or mutations, inside the endometrium's cell's DNA. This causes healthy cells, which grow, multiply, and die at a fixed rate, to mutate into abnormal cells, which do not die at a set time and will grow and multiply uncontrollably. The buildup of these abnormal cells creates a mass (tumor) (mayoclinic.org). In addition, damaged or defective DNA can change important genes that control cell growth. When the genes are damaged, this can cause uncontrollable growth that could cause cancer (cancer.org). Our project looked at mitochondrial DNA (mtDNA) templates derived from blood serum DNA extracts from EC patients to determine if mutations can be detected in the blood.




Figure 1. mtDNA mutations & heteroplasmy identified in three EC patients. Variants for patients 1, 2, and 3 are indicated on the outside of the map by P1, P2, and P3, respectively, and the percentage heteroplasmy for each mutation is reported.

Modified from, https://en.wikipedia.org/wiki/Endometrial cancer and https://doi.org/10.3390/life12040562

Methods

Starting PCR

TC Water, MM, Fwd/Rev Primers, and template were added.

Electrophoresis

1% agarose (6.1 V/cm) for 1.5hrs & 1.2% agarose (6.8 V/cm) for 1.6hrs were used.

Running PCR

Number of cycles varied on the amount of template used.

Extraction

Amplicon extraction was done using the E.Z.N.A. kit.

TC water - Tissue Culture Water mtDNA mitochondrial DNA

Quantification

DNA was quantified using Qubit 1X dsDNA HS Assay Kit.

PCR - Polymerase Chain Reaction MM - Master Mix

Table 1. EC tumor-specific DNA templates, and primers used to add Next-Generation Sequencing barcodes to

PCR amplicons.						Pair			
						Forward 1 AATGATACGGCGACCACCGAGATCTACAC AACCCCTC ACACTCTTTCC			
Patient & Mutation	Primers used for PCR	Template DNA (ng)	PCR Cycle No. ^a	Amplicon Conc. (ng/µl)	Total DNA (ng) ^b	Forward 2		TACGGCGACCACCGAGATCTACAC TCCGCGAA ACACTCTTTCCCTA	
						Forward 3	AATGA	TACGGCGACCACCGAGATCTACAC AACCCCTC ACACTCTTTCCCTA	
						Forward 5	AATGA	TACGGCGACCACCGAGATCTACAC CAGATCCA ACACTCTTTCCCTA	
G10401A, Patient 3	For 7, Rev 7	10	15	(ng/μι) 8.53	298.6	Forward 6	AATGA	TACGGCGACCACCGAGATCTACAC CGTACTAG ACACTCTTTCCCTA	
						Forward 7	AATGA	TACGGCGACCACCGAGATCTACAC CTCTCGTC ACACTCTTTCCCTA	
						Forward 8	AATGA	TACGGCGACCACCGAGATCTACAC GTAGAGGA ACACTCTTTCCCTA	
						Forward 9	AATGA	TACGGCGACCACCGAGATCTACAC CAGATCCA ACACTCTTTCCCTA	
T146C, Patient 3	For 6, Rev 6	10	15	32.53	1138.6	Forward 11	AATGA	TACGGCGACCACCGAGATCTACAC AAGAGGCA ACACTCTTTCCCTA	
						Forward 12	AATGA	TACGGCGACCACCGAGATCTACAC ACTTGACG ACACTCTTTCCCTA	
С16270Т,	For 9 Day 9	10	1 Г	0 50	200				
Patient 2	For 8, Rev 8	10	15	8.58	300	Reverse 1	CAAGC	AGAAGACGGCATACGAGAT GTCCGAGG GTGACTGGAGTTCAGAC	
G10644A, Patient 3	For 12, Rev 12	10	15	24.01	840.4	Reverse 2	CAAGC	AGAAGACGGCATACGAGAT ATAGAGAG GTGACTGGAGTTCAGAC	
						Reverse 3	CAAGC	AGAAGACGGCATACGAGAT CATCCGAA GTGACTGGAGTTCAGACG	
						Reverse 5	CAAGC	AGAAGACGGCATACGAGAT CGGAGAGA GTGACTGGAGTTCAGAC	
G12007A, Patient 2	For 9, Rev 9	21	8	12.72	445.2	Reverse 6	CAAGC	AGAAGACGGCATACGAGAT CGCTATGT GTGACTGGAGTTCAGACG	
						Reverse 7	CAAGC	AGAAGACGGCATACGAGAT TCTGTTGG GTGACTGGAGTTCAGACG	
						Reverse 8	CAAGC	AGAAGACGGCATACGAGAT TAGCCGCG GTGACTGGAGTTCAGAC	
G15995A, Patient 1	For 3, Rev 3	10	15	22.43	785.1	Reverse 9	CAAGC	AGAAGACGGCATACGAGAT TAGCCGCG GTGACTGGAGTTCAGAC	
						Reverse 11	CAAGC	AGAAGACGGCATACGAGAT AGCTAGAA GTGACTGGAGTTCAGACG	
						Reverse 12	CAAGC	AGAAGACGGCATACGAGAT CTAGTCGA GTGACTGGAGTTCAGACG	
T9179C, Patient 1	For 2, Rev 2	10	15	33.09	1,158.20	Lane 1 Lane 2 Lane	3 Lane 4 Lane 5	Figure 2. G10401A gel. Lanes 1-4 G10401A	
C16327T, Patient 1	For 11, Rev 11	10	15	17.04	596.4		amplicon scaled up for extraction, & lane 5 had negative control [contained no template].		
T16298C, Patient 1	For 5, Rev 5	12	15	17.84	624.4		5		
T6481C, Patient 1	For 1, Rev 1	21	10	16.27	569.5			Next Generation Sequencing	

a All PCRs were done using Phusion DNA polymerase with GC buffer (F-532L). PCR Conditions: 98 degrees for 30 seconds, (98 degrees for 10 seconds, 62 degrees for 30 seconds, 72 degrees for 30 seconds)x8-15 cycles, 72 degrees for 5 minutes, 4 degrees for holding.

b Following gel extraction, all samples were eluted with 35 μ l of TC water.


Discussion

We gratefully acknowledge and thank The Simmons Cancer Institute (SCI) Next-generation amplicon sequencing revealed that at least one tumorat SIU and the SIU School of Medicine for supporting this research specific heteroplasmic mtDNA mutation is detectable at ≥0.35% using through a Simmons Cancer Institution Team Science Grant, as well as the our method. The results from this research could present a non-invasive R15 Grant from NIH (M.J.Y.). Also, this work was supported by the SI testing option for those with endometrial carcinoma: a simple blood test Bridges to the Baccalaureate program (T.L.S.). We thank William Browning to search for mtDNA mutations. This would not only be non-invasive but & Pabitra Khadka for editing this poster, Carolyn Young for Figure 1, also make it easier to test for EC regularly. This could mean possibly Mostafijur Rahman for assisting with gel extraction, and Laxmi Sagwancatching cancer that has recurred earlier and offering a higher chance of Barkdoll and SI Bridges for this opportunity. remission, as EC is most likely to recur in the first few years after treatment (Young *et al*.). In addition, certain types of EC and cancer References treatments have been connected to being at an elevated risk of select second cancers, such as breast, colon, rectal, lung, lymphoma, bladder, Matthew J. Young, et al. "Identification of Somatic Mitochondrial DNA Mutations, kidney, vaginal, soft tissue, and acute leukemia (cancer.org). Looking at Endometrial Cancer Patients." Life, 2022. the big picture and future research, if the results were to confirm that 2. Mayo Clinic, 2021 May 20. "Endometrial Cancer, Symptoms & Causes" mtDNA mutation can be used as a biomarker, there could be fine-tuning https://www.mayoclinic.org/diseases-conditions/endometrial-cancer/symptoms-causes/sycof the process we used. There could also be research looking at 20352461#:~:text=Endometrial%20cancer%20is%20a%20type,is%20sometimes%20called%20uteri ne%20cancer expanding into being able to detect other types of cancers with this or a 3. Cancer.org similar technique.



Results

Table 2. Primers for Amplicon Next Generation Sequencing.



~300bp

After quantification, the DNA was sent off to our collaborator for **Next-Generation Amplicon Sequencing**, which will detect mutations of the mtDNA. We are still currently awaiting the results.

Acknowledgments/Funding

4. World Cancer Research Fund International, 2022 March 23. "Endometrial Cancer Statistics" https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/

Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three

